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Abstract
Radiation planning for cancer therapy is becoming
more and more dependent on the prediction of micro-
scopic tumor spread to regional lymph nodes for its
success. It is known that microscopic spread tends
to follow established lymphatic drainage pathways in
the head and neck based on the location of the pri-
mary tumor. In this paper, we propose a novel model
for the prediction of regional lymphatic involvement
of head and neck squamous cell carcinoma based on
primary tumor location and T-stage. The proposed
model operates from ﬁrst anatomical principles and
basic stochastic techniques, and is validated against
surgical data.
Introduction
Radiation Oncology is one of the physician’s best tools
for treatment of tumors of the head and neck. Recent
developments in the ﬁeld have allowed for more pre-
cise dosages of radiation to irregular target volumes of
the neck, making it a reasonable alternative to surgery
in many cases. The effectiveness of these treatments,
however, depends critically on the delineation of these
target volumes to include regional lymph nodes to
which metastases may have occurred.
Currently, clinicians must draw target volumes by
hand. Because tumors metastasize along lymphatic
drainage pathways, this process requires them to es-
timate many variables such as which lymphatic chan-
nels the tumor has taken and how far along them it has
spread. Lymph nodes to which a tumor has spread can-
not always be made visible with any imaging technol-
ogy and there does not exist a computational tool to
estimate their location; although some nodes may be
recognized by PET scans, the treatment of occult dis-
eased lymph nodes is critical in preventing recurrence
and further metastasis.
Clinicians have deﬁned a number of regions of the
head and neck in order to establish some uniformity
in terms of related lymphatic chains and node clus-
ters.1, 2 These regions frequently make delineation
of target volumes easier because entire regions are
treated rather than single lymph nodes or smaller clus-
ters. Surgical data has offered some insight into which
regions are likely to contain positive lymph nodes in
clinical situations and have shown some patterns in
terms of regional spread. Generally, the longer a tu-
mor is present and the larger it grows, the more likely
distant lymphatic groups are to be affected.
The goal of the work that follows is to produce
a theoretical model that predicts the distribution of
microscopic spread in the head and neck as well as
probabilities of ﬁnding positive nodes in each region.
The approach uses a simple sequence of Markov mod-
els in conjunction with known lymphatic anatomical
information in the Foundational Model of Anatomy
(FMA)3 toproduceaprogressionofnodalregionswith
assigned probabilities of disease. Previous work in this
area has attempted to establish rules for the involve-
ment of lymph nodes but has done so based on surgical
data and not from ﬁrst principles.4
Nodal Regions of the Head and Neck
Cancers of the head and neck tend to follow a rea-
sonably predictable pattern of growth and spread de-
ﬁned most importantly by the anatomical surroundings
of the initial tumor. Generally, the lymphatic spread
follows the drainage patterns of regional lymph nodes
and chains. Although surgical techniques originally
incited the establishment of regions of the head and
neck,5, 6 these regions are also useful in radiation ther-
apy. Our model uses the established regions I-VI as
well as proposed regions B (Buccal), P (Parotid), and
RP (retropharyngeal)7 in order to generalize the pre-
dicted lymphatic spread (see Table 1).
Published Data
A small number of surgical studies have been per-
formed on patients with tumors of the head and neck
and serve as our primary method of validation. Un-
fortunately, very few studies detail both the extent of
lymphatic metastases and the initial tumor’s T-stage.Table 1: Clinical Regions of the Head and Heck
Region Nodal Group
Ia Submental
Ib Submandibular
IIa (Anterior) Upper Jugular
IIb (Posterior) Upper Jugular
III Middle Jugular
IV Lower Jugular
Va (Upper) Posterior Triangle
Vb (Lower) Posterior Triangle
VI Anterior Compartment
P Parotid
B Buccal
RP Retropharyngeal
Because of the nature of the model, however, valida-
tion can be performed both with metastatic correla-
tions to T-stage and metastatic correlations to nodal
regions separately.
The surveys gathered for use in validation varied
both in breadth and depth. Studies or aspects of stud-
ies that were deemed too small (n < 20) or too biased
(e.g. only included patients with aggressive disease)
were discarded. Additionally, studies and study com-
ponents involving anatomy with which the FMA does
not record lymphatic drainage had to be discarded.
Anatomical Information
Anatomical information for the model was retrieved
from the FMA, which contains a reasonably complete
set of lymphatic drainage pathways in the form of
lymph chains for the head and neck with the notable
exception of lymph nodes, which tend to vary between
patients. Becausethepurposeofthemodelistopredict
regions of spread, however, the lack of speciﬁc nodes
was not considered problematic.
One shortcoming of the FMA was the lack of in-
formation about the head and neck regions for each of
the lymphatic chains. This became particularly prob-
lematic because certain lymph chains span multiple re-
gions; for example, the jugular lymphatic chain spans
both region VI and region IV. In order to make the
model more coherent, we supplemented the FMA’s
anatomical data with these clinical regions to form an
extended set of lymphatic chains that can be divided
into subunits, where a single subunit is a regional part
(region) of a lymphatic anatomical entity, for exam-
ple, the part of the superior deep lateral cervical lym-
phatic chain in region III. The lymphatic drainage of
each tumor site, thus, can be divided into a number of
positions, wherepositioniconsistsoftheregionalsub-
units that have exactly i subunits prior to them along
any possible drainage pathways from the primary tu-
mor site.
Model Speciﬁcations
Assumptions
Because the model is intended to derive predictions
from anatomical principles, it assumes several things,
the most important of which is that the probability of
a metastasis at a particular position in the lymphatic
drainage pathways depends only on the presence of
cancer in the previous position. This implies that the
spreadofcancercannotskipasiteinthedrainagepath-
way. Although this assumption is probably not biolog-
ically true, we feel that it is necessary to maintain the
simplicity of the model and that it provides more clin-
ically relevant data by allowing a physician to discern
which nodes are upstream from a particular location of
known or suspected disease. Additionally, the model
assumes a constant relationship between T-stage and
nodal metastasis; this is necessary because, in a radio-
logical treatment scenario, the physician is unlikely to
have any additional information about the tumor.
Input
The input to the model is a primary tumor site and a T-
stage (1-4). The primary tumor site is used to query
the FMA for lymphatic drainage and the lymphatic
drainage of its subparts (for example, if the primary
tumor site is “Ear” then the lymphatic drainage for the
“Pinna” would also be queried), all of which is supple-
mented with head and neck clinical region information
to form a series of lymphatic drainage positions from
the primary site.
Structure
The model itself is made of a series of Markov mod-
els, one for each position along the lymphatic drainage
pathway of the primary site. An additional “position
0” Markov model represents the primary tumor site,
which has a different Markov model than the lym-
phatic regions, is added; the philosophy for this deci-
sion is that the initial tumor is unlikely to grow at rates
equivalent to those of the diseased lymph nodes. Each
Markov model represent a position along the lym-
phatic drainage pathway and has ﬁve states, 0-4, each
representing a state of growth of the cancer at that lo-
cation. We use the term “state” here instead of “stage”
in order to distinguish between the T or N stage of the
tumor and an abstract overall state of growth. State 0
represents no cancer and state 4 represents consider-
able disease. Each state s also has associated with it a
probability qs of metastasizing to the next position in
the chain such that, given the probability distributionFigure 1: A diagram of two positions of the Markov
model used in the model. Each edge represents a tran-
sition probability from one state of growth to another
while each dotted edge represents an ‘output’ proba-
bility of metastasis, which affects the probability of the
next position’s distribution being in state 1.
pi (0 ≤ i ≤ 4) of being in state i at a speciﬁc position
in the chain, the probability p0 that the next position
downstream will become diseased from microscopic
spread is
p0 =
4 X
s=0
psqs. (1)
For a diagram of the Markov model, see ﬁgure 1.
Execution
Initially, the probability distributions of each of the po-
sitions are set to be in state 0 with probability 1 with
the exception of the 0th position (the primary tumor
site), which has probability 1 of being in state 1. The
model is then run for 4 × T iterations (where T is the
T-stage of the cancer). The number of iterations was
chosen arbitrarily and could be chosen as any mono-
tonically increasing function of T so long as it is not
changed after training the model. This ﬂexibility is
possible because the length of time represented by an
iteration is abstract and the total time of growth is
likely unknown. After each iteration, the probability
of a given position metastasizing to the next position
in the chain is calculated using equation (1), adjusted
against the probability that it has already metastasized,
subtracted from the probability that the next position
is in stage 0, and added to the probability that the next
position is in state 1. The probability %k that position
k in the pathway has already metastasized is followed
in order to assure that metastatic probabilities are kept
to scale; assume, for example, that the probability of
metastasis from position 5 to position 6 was calculated
after two iterations to be µ2. Position 6’s probability
distribution will be accordingly updated and %5 will be
set equal to µ2. After the next iteration, the probability
will be µ3 > µ2; if µ2 = 0.5, then the net probability
of metastasis will be greater than 1.0. Instead of allow-
ing this, the actual update to position 3’s probability
distribution is not µ3, but (µ3 − %5). This causes the
probability distribution of each position to reﬂect the
total probability that metastasis has occurred up to that
iteration. The probability matrix P used in the Markov
models and the probability of metastasis m are given
below:
P =






1.00 0.00 0.00 0.00 0.00
0.00 0.50 0.50 0.00 0.00
0.00 0.00 0.50 0.50 0.00
0.00 0.00 0.00 0.50 0.50
0.00 0.00 0.00 0.00 1.00






m =
 
0.00 0.60 0.70 0.80 0.90
T
Additionally, the matrix P0 and corresponding m0 vec-
tor are used for the initial tumor site:
P0 =






1.00 0.00 0.00 0.00 0.00
0.00 0.90 0.10 0.00 0.00
0.00 0.00 0.90 0.10 0.00
0.00 0.00 0.00 0.90 0.10
0.00 0.00 0.00 0.00 1.00






m0 =
 
0.00 0.20 0.40 0.60 0.80
T
The probabilities of the matrix P were chosen with the
philosophy of keeping the model as simple as possible;
the probability of a position’s cancer growing or stay-
ing the same is one half. The probability of metastasis
m was chosen to be simple, but was chosen relatively
high because of the tendency for multiple nodal groups
in multiple regions to be involved in any cancer (thus
for cancer to move relatively easily through a lym-
phatic pathway). The matrix P0 was chosen in order
to give a reasonable distribution of time in each state
for a long simulation (e.g. for T = 4, 16 iterations),
and the vector m0 was chosen to be a simple linear dis-
tribution over the probability space. For a pseudo-code
representation of the stochastic process of the model,
see ﬁgure 2. Note that the model used in this paper
was not trained on data but chosen arbitrarily with the
above justiﬁcations as a proof of concept.
We deﬁne the variables used in the pseudocode as
follows:
Let n be the number of positions in the lymphatic
pathway downstream from 0.
Let g be the number of states of growth above 0 (4).
Let P and P0 be transition probability matrices and m
and m0 be metastasis probability vectors, as described
above.
Let {%0,%1,...,%n−1} be the set of probabilities that
state j has already metastasized (initially 0).
Let {p(1),p(2),...p(n)} be the set of vectors that ex-
press the probability that a given position is in a givenfor i = 1...4T
do for j = n − 1,n − 2,...,2,1
do p(j) ← Pp(j)
p
(j+1)
0 ← p
(j+1)
0 + m˙ p(j) − %j
%j ← m˙ p(j)
done
p(0) ← P0p(0)
p
(1)
0 ← p
(1)
0 + m0 ˙ p(0) − %0
%0 ← m0 ˙ p(0)
done
Figure 2: Pseudo-code describing the stochastic pro-
cess in the lymphatic drainage model.
state of growth; p
(j)
k is the probability that position j
is in state k of growth.
Let T be the T-stage of the primary tumor.
Following this procedure, the probability of micro-
scopic presence at any given state j is equal to the sum:
g X
i=1
p
(j)
i
After the model has been run for the appropriate
number of iterations, the net probability of presence of
cancer at each state is calculated by summing over the
probabilities of cancer at each growth state. Note that
this is not a Monte Carlo approximation of the prob-
abilities but an exact analytical determination of the
model’s distribution given the inputs.
Validation
In order to validate the proposed model, we have com-
pared it to two surgical studies. The studies involved
patients with cancer of the oropharynx and hypophar-
ynx (n = 204)8 and cancer of the oral cavity including
the tongue, ﬂoor of mouth, gum, retromolar trigone,
and cheek (n = 501).9 The results of our model’s pre-
dictions (each run with an initial T-stage of 1 or 4),
along with the results of each study, are summarized
in tables 2 and 3. In both tables the percentages of
the model are predicted probabilities of ﬁnding micro-
scopic disease in lymph nodes at that site.
Discussion
The intent of the model is to demonstrate the plausibil-
ity of quantitatively predicting the microscopic spread
of tumors using anatomical data and basic stochastic
techniques. Accordingly, the model was kept inten-
tionally simple. An ideal model would likely employ
different transition matrices for different anatomical
units and would be trained based on extensive analysis
Table 2: Comparison of our model’s predictions with
a surgical study of the oral cavity.9 Percentages are
given.
I II III IV V VI
Tongue (Prophylactic Dissection)
Model (T = 1) 28 19 16 0 0 0
Study 14 19 16 3 0 0
Tongue (Therapeutic Dissection)
Model (T = 4) 50 42 35 23 0 18
Study 32 50 40 20 0 0
Floor of Mouth (Prophylactic Dissection)
Model (T = 1) 28 12 12 19 28 19
Study 16 12 7 2 0 0
Floor of Mouth (Therapeutic Dissection)
Model (T = 4) 50 35 35 42 50 42
Study 53 34 32 12 7 0
Gum (Prophylactic Dissection)
Model (T = 1) 28 19 19 12 19 12
Study 27 21 6 4 2 0
Gum (Therapeutic Dissection)
Model (T = 4) 50 42 42 35 42 35
Study 54 46 19 17 4 0
Table 3: Comparison of our model’s predictions with a
surgical study of oropharynx and hypopharynx.8 Per-
centages are given. Note that prophylactic dissection
of the piriform sinus and pharyngeal wall were omitted
because of a small sample size (n < 20). Additionally,
results on the pharyngeal wall and piriform sinus or
omitted because of the absence of lymphatic drainage
information in the FMA.
I II III IV V VI
Base of tongue (Prophylactic Dissection)
Model (T = 1) 0 19 19 12 0 6
Study 0 19 14 9 5 0
Base of tongue (Therapeutic Dissection)
Model (T = 4) 0 42 42 35 0 29
Study 10 72 41 21 9 0
Tonsillar fossa (Prophylactic Dissection)
Model (T = 1) 0 28 19 12 0 6
Study 4 30 22 7 0 0
Tonsillar fossa (Therapeutic Dissection)
Model (T = 4) 0 50 42 35 0 29
Study 17 70 42 31 9 0
of surgical data. Each Markov model in the process
is essentially a hidden Markov model with probabil-
ities of metastasis as outputs; thus methods exist for
training ideal outputs given a set of acceptable proba-
bilities.
In examining the results of the validation, there is ahigh correlation between the predictions for regions II,
III, and IV of the neck and a much lower correlation
for region I. Many lymphatic pathways drain from re-
gion II to III to IV, which are widely conjectured to
be the most predictable of the head and neck’s lym-
phatics. Regions IV, V, and VI, however, were fre-
quently over-predicted by the model (e.g. the ﬂoor of
mouth and the gum). This may be due in part to the
lack of information concerning the proportion of lym-
phatic drainage that goes to various lymphatic chains.
For example, in the gum (gingiva), the submandibu-
lar lymphatic chain (I) is efferent to both the jugulo-
omohyoid chain (III) and the superior deep lateral cer-
vical lymphatic chain (V), but probably does not drain
as intensely into the latter as the former. Additionally,
the model only attempts to predict metastasis to lymph
nodes on established drainage pathways; no attempt is
made to explain the microscopic spread to regions that
may simply be nearby or that may receive metastases
via other means. For example, the base of the tongue
(listed in the FMA as “Root of tongue”) drains primar-
ily through the basal lingual lymphatic tree (B) which
drains into the jugulo-omohyoid lymphatic chain (III)
and the jugulodigastric lymphatic chain (II). Based on
the base of tongue’s proximity to region I, it is not sur-
prising that tumors might be found there surgically, but
because the lymphatic drainage does not include re-
gion I, our model did not predict it.
An additional problem that was encountered was the
lack of speciﬁcity in the studies and the difference in
vocabulary of the FMA. The “tonsillar fossa”, for ex-
ample, being an anatomical space, is not listed in the
FMA, but the “Palatine tonsil” and “Soft palate” might
be considered reasonable alternatives. Additionally,
because the model treats all parts of a queried anatom-
ical unit equally, the reported probabilities are equiva-
lent to the sum of queries of all of the unit’s parts. For
example, a query on the cheek would be equivalent to
taking the combined results from a query of the wall
of the cheek and of the Parotid gland.
Although the correlation to surgical data is not per-
fect, we feel that the initial results demonstrate the
potential for a similar model to accurately predict re-
gional tumor spread in the lymphatic system. Because
the best results were obtained for areas in which lym-
phatic drainage extends throughout the neck (e.g. the
tongue) and because the model tends to over-predict
rather than under-predict tumor metastasis, we sus-
pect that the addition of information regarding the rel-
evance of drainage pathways would most improve the
results. The relative success suggests that a stochastic
approach to metastatic prediction is plausible. Future
work would establish a more complete anatomical and
probabilistic model.
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